Lengthening Omalizumab Dosing Interval in Treatment of Moderate to Severe Persistent Asthma

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.306
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Omalizumab in Patients With Severe Asthma and Persistent Sputum Eosinophilia

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Utility of Impulse Oscillometry in Patients With Moderate to Severe Persistent Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2016English

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

Real-Life Effectiveness of Omalizumab in Severe Allergic Asthma Above the Recommended Dosing Range Criteria

Pediatrics
Child HealthPediatricsPerinatology
2017English

Effect of Omalizumab on Lung Function and Eosinophil Levels in Adolescents With Moderate-To-Severe Allergic Asthma

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2020English

Omalizumab Treatment in Brittle Asthma

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2014English

Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

First Experience With Omalizumab in a Child With Severe Persistent Asthma in Turkey: Case Report

Turkiye Klinikleri Journal of Medical Sciences
Medicine
2010English

Prs10 - Population Health Impact of Omalizumab Over 11 Years of Use in Ireland in Moderate to Severe Allergic Asthma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy